Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

ADR REPORT
[View FULLTEXT] [Download PDF
 
Year : 2009  |  Volume : 55  |  Issue : 2  |  Page : 139-140  

Azathioprine induced pancytopenia: A serious complication

V Hadda, BD Pandey, R Gupta, A Goel 
 Department of Medicine, All India Institute of Medical Sciences, New Delhi - 110 029, India

Correspondence Address:
V Hadda
Department of Medicine, All India Institute of Medical Sciences, New Delhi - 110 029
India

Azathioprine is commonly used for treatment of lupus nephritis. Myelosuppression is known to occur with azathioprine, but severe pancytopenia is uncommon. A 23-year-old man with lupus nephritis was initially treated with intravenous cyclophosphamide pulses and oral prednisolone along with enalapril and frusemide. Following six months of cyclophosphamide, he was initiated on oral azathioprine as maintenance therapy. He subsequently returned with febrile neutropenia and severe bone marrow suppression. Fever responded to broad spectrum antibiotics and his counts gradually improved following granulocyte-macrophage colony stimulating factor. When last seen in October, he was symptom free and disease activity in control. We suggest that physicians remain sensitive to possibility of azathioprine induced severe bone marrow suppression. Frequent monitoring of blood counts is probably the best way to avoid this complication specially, where testing for thiopurine methyltransferase is not available.


How to cite this article:
Hadda V, Pandey B D, Gupta R, Goel A. Azathioprine induced pancytopenia: A serious complication.J Postgrad Med 2009;55:139-140


How to cite this URL:
Hadda V, Pandey B D, Gupta R, Goel A. Azathioprine induced pancytopenia: A serious complication. J Postgrad Med [serial online] 2009 [cited 2021 Jun 21 ];55:139-140
Available from: https://www.jpgmonline.com/article.asp?issn=0022-3859;year=2009;volume=55;issue=2;spage=139;epage=140;aulast=Hadda;type=0


 
Monday, June 21, 2021
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer